Benzinga Pro
Marketfy
Financial Data & APIs
Events
Premarket Prep
Membership is Free
What are you waiting for? Sign up now!
Name:
Username available!
Username taken!
Email:
Email available!
Email taken!
Password:
Leave blank:
OR
Free Account Login
Click here to access your premium account
Username or email:
Password:
OR
Forgot password?
Contribute
Login
Join
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Retail Sales
Offerings
IPOs
Insider Trades
Biotech/FDA
Markets
Pre-Market
After Hours
Movers
Forex
Commodities
Options
Binary Options
Bonds
Futures
Global Economics
Previews
Reviews
Small-Cap
Cryptocurrency
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
ETFs
Tech
Start-Ups
Fintech
Investing
Best Online Brokers
Personal Finance
Compare Brokers
TD Ameritrade Review
Ally Invest Review
Etrade Review
Personal Capital Review
Tradestation Review
Market Overview
Tickers
Articles
Keywords
Search by keyword...
googlecse
More From AMGN
Summary
Ideas
Twitter ($AMGN)
All News
Analyst Coverage
Analyst Ratings
News Coverage
News
General
Contracts
Dividend Summaries
Dividend Calendar
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Press Releases
Earnings
Earning Summaries
Earnings Calendar
Guidance Summaries
Amgen Inc.
AMGN
:NASDAQ
Add to Watchlist +
{{ portfolio.portfolio_name }}
You have no watchlists at this time, click "Manage watchlists" to create your first watchlist.
Manage watchlists
Sector:
Healthcare
Industry:
Biotechnology
174.83
2.89 (1.68%)
After Hours 174.87
(%)
Data as of Apr 25, 2018
Prev. Close
171.94
Price Open
173.66
Volume
4,693,756
Day's Range
170.34 - 175.44
52 Wk Range
152.16 - 201.23
50 Day Moving Avg.
178.99
PE Ratio
63.918216
Shares Outstanding
730.70M
Market Cap
127.75B
Trade AMGN stock with
recommended broker Ally Invest
. Commissions as low as $3.95.
1d
5d
1m
3m
1y
5y
YTD
Analyst Rating
View All Ratings
Date
Research Firm
Action
Current
Target
4/25/18
Morgan Stanley
Maintains
Overweight
Overweight
200.0
4/05/18
Barclays
Maintains
Equal-Weight
Equal-Weight
180.0
2/05/18
Atlantic Equities
Downgrades
Overweight
Neutral
0.0
Headlines
Press Releases
Benzinga's Top Analyst Calls From April 25, 2018
Bill Haddad
Wed, 25 Apr 2018 14:43:24 -0400
Baird: Biogen A Buy On M&A Prospects, Underappreciated Franchises
Elizabeth Balboa
Wed, 25 Apr 2018 12:11:44 -0400
Cowen Out Positive Following Amgen Earnings, Calling It One Of The Better Financial Reports For The Co. In Some Time; Says That The Stock Is Inexpensive And Could Benefit From Significant Multiple Expansion
Eddie Staley
Wed, 25 Apr 2018 09:49:14 -0400
Morgan Stanley Maintains Overweight on Amgen, Lowers Price Target to $200.00
Vick Meyer
Wed, 25 Apr 2018 09:03:41 -0400
Benzinga's Biotech Pulse: Takeda Sweetens Shire Offer Again, Menlo's Woes Abound, Earnings Fail to Boost Amgen
Shanthi Rexaline
Wed, 25 Apr 2018 07:46:04 -0400
Amgen Says Board Increased Amount Authorized Under Co's Stock Repurchase Program by Additional $5B
Charles Gross
Wed, 25 Apr 2018 06:19:10 -0400
Amgen Sees FY18 Adj. EPS $12.80-$13.70 vs $13.48 Est., Sales $21.9-$22.8B vs $22.6B Est.
Eddie Staley
Tue, 24 Apr 2018 16:02:30 -0400
Amgen Q1 EPS $3.47 Beats $3.24 Est., Sales $5.6B Beats $5.43B Est.
Eddie Staley
Tue, 24 Apr 2018 16:01:45 -0400
Goldman Sachs Neutral On Alder Biopharma As Launch Of Migraine Treatment Approaches
Elizabeth Balboa
Tue, 24 Apr 2018 12:49:45 -0400
Reuters Reported That Express Scripts Is Telling Drugmakers That The Current Pricing Model Is Broken; Co. Is Taking Aim At Amgen And Other Makers Of New Migraine Medicines To Try And Fix It
Eddie Staley
Tue, 24 Apr 2018 06:33:10 -0400
{{ story.title }}
{{ story.author }}
{{ story.created }}
Show more
Loading articles...
Amgen Reports First Quarter 2018 Financial Results
PRNewswire
1 day ago
Technical Perspectives on Biotech Stocks -- Alnylam Pharma, Amgen, Amicus Therapeutics, and Ampio Pharma
PRNewswire
5 days ago
Amgen Announces Webcast Of 2018 First Quarter Financial Results
PRNewswire
6 days ago
Amgen Presents First-Of-Its-Kind Data At AAN Annual Meeting Reinforcing Robust And Consistent Efficacy Of Aimovig™ (erenumab) For Migraine Patients With Multiple Treatment Failures
PRNewswire
Apr 17, 2018
Amgen Announces Rhode Island Will Be Location Of First US Next-Generation Biomanufacturing Plant
PRNewswire
Apr 10, 2018
Amgen To Present New Pre-Clinical Data Showcasing Robust Approach To Evaluating Potential Anti-Cancer Therapies At AACR 2018
PRNewswire
Apr 09, 2018
European Commission Approves Expanded Indication For Amgen's XGEVA® (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma
PRNewswire
Apr 03, 2018
FDA Approves BLINCYTO® (blinatumomab) To Treat Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia In Adults And Children
PRNewswire
Mar 29, 2018
Corvidia Therapeutics Appoints Marc de Garidel as Chief Executive Officer
Business Wire
Mar 29, 2018
Amgen Receives Positive CHMP Opinion Recognizing That Repatha® (evolocumab) Prevents Heart Attacks And Strokes
PRNewswire
Mar 23, 2018
{{ story.title }}
{{ story.author }}
{{ story.created }}
Show more
Loading articles...
Partner Headlines
Biotech Stock Roundup: PRTA Down, AMGN Revises View, BIIB Misses on Sales
Zacks
5 hours ago
Amgen Inc. 2018 Q1 - Results - Earnings Call Slides
Seeking Alpha
7 hours ago
AbbVie files U.S. marketing application for plaque psoriasis med risankizumab
Seeking Alpha
13 hours ago
Facebook Steps Up To The Earnings Plate, Comcast Bids For Sky (Wall Street Breakfast Podcast)
Seeking Alpha
13 hours ago
Wall Street Breakfast: Facebook Back In The Spotlight
Seeking Alpha
15 hours ago
Amgen's (AMGN) CEO Bob Bradway on Q1 2018 Results - Earnings Call Transcript
Seeking Alpha
21 hours ago
Mr. Market Grasps the Esoteric
GuruFocus
1 day ago
Amgen Q1 revenues up 2%; earnings up 12%; cash flow up 14%; earnings guidance raised; shares up 1% after hours
Seeking Alpha
1 day ago
Amgen beats by $0.22, beats on revenue
Seeking Alpha
1 day ago
Hemenway Trust Co LLC Buys Fiserv Inc, Celgene Corp, NVIDIA Corp, Sells MarketAxess Holdings ...
GuruFocus
1 day ago
{{ story.title }}
{{ story.author }}
{{ story.created }}
Show more
Loading articles...
Earnings
View Earnings
Q1 2018
EST
Actual
Surprise
EPS:
3.22
3.47
0.25
Rev:
5.41B
5.55B
144.00M
Q2 2018
EST
Actual
Surprise
EPS:
Expected
2018-07-24
Rev:
Brokerage Center
Compare All Online Brokerages